Teva Respiratory Announces Positive Results From Phase III Trial Of BDP HFA Nasal Aerosol In Seasonal Allergic Rhinitis

Sunday, Sep. 12th 2010 6:23 AM

Teva Respiratory announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to a placebo.

VN:F [1.9.22_1171]
Rating: 5.0/5 (1 vote cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)
Teva Respiratory Announces Positive Results From Phase III Trial Of BDP HFA Nasal Aerosol In Seasonal Allergic Rhinitis, 5.0 out of 5 based on 1 rating
Posted on Sunday, Sep. 12th 2010 6:23 AM | by Share of Cost | in Share of Cost | No Comments »

Leave a Reply